| Name | Title | Contact Details |
|---|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio.
Samsung Biologics is the most qualified worlds leading Contract Development, Manufacturing and Research Organization, committed to quality-driven development, manufacturing of biopharmaceutical products.
At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies worldwide.
At ChemNavigator we help research organizations identify and procure the chemistry they need for drug discovery and agrochemical research. We serve researchers in medicinal, computational, and synthetic chemistry as well as chemical procurement
Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.